TCBP to Present at Sequire Investor Summit 2025
TC BioPharm (NASDAQ: TCBP), a clinical-stage biotechnology company focused on developing allogeneic gamma-delta T cell therapies for cancer and other conditions, has announced its participation in the upcoming Sequire Investor Summit 2025. The company's CEO, Bryan Kobel, will deliver a corporate overview presentation at the event, which is scheduled for January 21-23, 2025, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico.
TC BioPharm (NASDAQ: TCBP), un'azienda biotech in fase clinica che si concentra sullo sviluppo di terapie a base di cellule T gamma-delta allogeniche per il cancro e altre condizioni, ha annunciato la sua partecipazione al prossimo Sequire Investor Summit 2025. Il CEO dell'azienda, Bryan Kobel, presenterà una panoramica aziendale durante l'evento, che si terrà dal 21 al 23 gennaio 2025, presso il Condado Vanderbilt Hotel a San Juan, Porto Rico.
TC BioPharm (NASDAQ: TCBP), una compañía de biotecnología en etapa clínica centrada en desarrollar terapias con células T gamma-delta alogénicas para el cáncer y otras condiciones, ha anunciado su participación en el próximo Sequire Investor Summit 2025. El director ejecutivo de la compañía, Bryan Kobel, dará una presentación sobre la empresa en el evento, programado del 21 al 23 de enero de 2025, en el Condado Vanderbilt Hotel en San Juan, Puerto Rico.
TC BioPharm (NASDAQ: TCBP)는 암 및 기타 질환을 위한 알로젠ic 감마 델타 T 세포 치료제를 개발하는 데 초점을 맞춘 임상 단계의 생명공학 회사로, 다가오는 Sequire Investor Summit 2025에 참여한다고 발표했습니다. 회사의 CEO인 Bryan Kobel은 2025년 1월 21일부터 23일까지 푸에르토리코의 산후안에서 열리는 행사에서 기업 개요 발표를 할 예정입니다.
TC BioPharm (NASDAQ: TCBP), une entreprise de biotechnologie en phase clinique axée sur le développement de thérapies à base de cellules T gamma-delta allogéniques pour le cancer et d'autres conditions, a annoncé sa participation au prochain Sequire Investor Summit 2025. Le PDG de l'entreprise, Bryan Kobel, fera une présentation de l'entreprise lors de l'événement, qui se tiendra du 21 au 23 janvier 2025 au Condado Vanderbilt Hotel à San Juan, Porto Rico.
TC BioPharm (NASDAQ: TCBP), ein biotechnologisches Unternehmen in klinischer Phase, das sich auf die Entwicklung von allogenen Gamma-Delta-T-Zelltherapien für Krebs und andere Erkrankungen konzentriert, hat seine Teilnahme am bevorstehenden Sequire Investor Summit 2025 bekannt gegeben. Der CEO des Unternehmens, Bryan Kobel, wird bei der Veranstaltung, die vom 21. bis 23. Januar 2025 im Condado Vanderbilt Hotel in San Juan, Puerto Rico, stattfindet, eine Unternehmensübersicht präsentieren.
- None.
- None.
The conference is scheduled for January 21-23, 2025, at the Condado Vanderbilt Hotel in San Juan,
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gamma-delta T cell therapies for cancer treatment with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue.
TC BioPharm is the leader in developing gamma-delta T cell therapies and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial in the treatment of acute myeloid leukemia using the Company's proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide.
Forward-Looking Statements for TC BioPharm
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the Company's intent or ability to affect any budget savings or execute on any M&A or capital raising strategy. These statements are based on management's current assumptions and are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. For other important factors that could cause actual results to differ materially from the forward-looking statements in this Current Report on Form 8-K, please see the risks and uncertainties identified under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and our other reports filed with the SEC, all of which is available on the Company's Investor Relations website at www.tcbiopharm.com and on the SEC website at www.sec.gov. All forward-looking statements reflect the Company's beliefs and assumptions only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to update forward-looking statements to reflect future events or circumstances.
View original content to download multimedia:https://www.prnewswire.com/news-releases/tcbp-to-present-at-sequire-investor-summit-2025-302347344.html
SOURCE TC BioPharm
FAQ
When and where is TC BioPharm (TCBP) presenting at the Sequire Investor Summit 2025?
What type of therapies is TCBP developing according to the announcement?
Who will represent TCBP at the Sequire Investor Summit 2025?
What is the current development stage of TCBP's therapeutic programs?
Where can investors find registration information for the Sequire Investor Summit 2025?
